Merrion commences drug delivery feasibility, option agreement with Rebel
Merrion claimed that the agreement will evaluate the ability of its patented Gipet technology to enhance the compounds’ clinical profile and provide a substantially improved product. On successful
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.